BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Pekka Jalovaara

25.08.2022

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 25 August 2022 11.30 a.m. (CEST)

BBS Bioactive Bone Substitutes Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Jalovaara, Pekka

Position: Member of the Board/Deputy member

Issuer: BBS Bioactive Bone Substitutes Oyj

LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION

Reference number: 743700BYSBP0PCR6N767_20220824195329_16

____________________________________________

Transaction date: 2022-06-17

Venue not applicable

Instrument type: SHARE

ISIN: FI4000260583

Nature of the transaction: SUBSCRIPTION

Transaction details

(1): Volume: 15,400 Unit price: 1.3 EUR

Aggregated transactions

(1): Volume: 15,400 Volume weighted average price: 1.3 EUR

____________________________________________

Transaction date: 2022-06-20

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522891

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

Transaction details

(1): Volume: 1,925 Unit price:  EUR

Aggregated transactions

(1): Volume: 1,925 Volume weighted average price:  EUR

____________________________________________

Transaction date: 2022-06-20

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522909

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

Transaction details

(1): Volume: 1,925 Unit price:  EUR

(2): Volume: NaN Unit price: NaN EUR

Aggregated transactions

(2): Volume: 1,925 Volume weighted average price:  EUR

For more information:

Ilkka Kangasniemi, CEO,
tel. +35840 7080307, e-mail: ilkka.kangasniemi@bbs-artebone.fi

Liisa Hukka, CFO,
tel. +35840 0611038, e-mail: liisa.hukka@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB, tel. +46 70 551 67 29, info@certifiedadviser.se

BBS in brief

BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi.

BBS-Bioactive Bone Substitutes Oyj:n shares have been listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

More information: www.bbs-artebone.fi